AIkido Pharma

AIkido Pharma is a biotechnology development company with a variety of early-stage small molecule anticancer drugs. AIkido Pharma's platform includes patented technologies from leading universities and researchers, and we seek to develop our innovative drugs through close collaborations with world-renowned institutions such as the University of Texas and Wake Forest University. Our diversified therapeutic pipeline includes treatments for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our pancreatic cancer treatment has shown positive preclinical results in clinically relevant transgenic mouse models, demonstrating inhibition of pancreatic tumor growth. The drug has also shown potential to overcome tumor cell resistance to existing chemotherapy drugs. Our AML drug is a next-generation targeted therapy designed to address multiple resistance mechanisms observed in current standard treatments. Additionally, we continuously seek to expand our pipeline to address unmet medical needs in the field of oncology.